Abstract:Abstract Background DNA methylation is a potential biomarker for early detection of breast cancer. However, robust evidence of a prospective relationship between DNA methylation patterns and breast cancer risk is still lacking. The objective of this study is to provide a systematic analysis of the findings of epigenome-wide DNA methylation studies on breast cancer risk, in light of their methodological strengths and weaknesses. Methods We searched major databases (MEDLINE, EMBASE, Web of Science, CENTRAL) from inception up to 30th June 2019, for observational or intervention studies investigating the association between epigenome-wide DNA methylation (using the HM450k or EPIC BeadChip), measured in any type of human sample, and breast cancer risk. A pre-established protocol was drawn up following the Cochrane Reviews rigorous methodology. Study selection, data abstraction, and risk of bias assessment were performed by at least two investigators. A qualitative synthesis and systematic comparison of the strengths and weaknesses of studies was performed. Results Overall, 20 studies using the HM450k BeadChip were included, 17 of which had measured blood-derived DNA methylation. There was a consistent trend toward an association of global blood-derived DNA hypomethylation and higher epigenetic age with higher risk of breast cancer. The strength of associations was modest for global hypomethylation and relatively weak for most of epigenetic age algorithms. Differences in length of follow-up periods may have influenced the ability to detect associations, as studies reporting follow-up periods shorter than 10 years were more likely to observe an association with global DNA methylation. Probe-wise differential methylation analyses identified between one and 806 differentially methylated CpGs positions in 10 studies. None of the identified differentially methylated sites overlapped between studies. Three studies used breast tissue DNA and suffered major methodological issues that precludes any conclusion. Overall risk of bias was critical mainly because of incomplete control of confounding. Important issues relative to data preprocessing could have limited the consistency of results. Conclusions Global DNA methylation may be a short-term predictor of breast cancer risk. Further studies with rigorous methodology are needed to determine spatial distribution of DNA hypomethylation and identify differentially methylated sites associated with risk of breast cancer. Prospero registration number CRD42020147244

Prognostic DNA methylation markers for hormone receptor breast cancer: a systematic review

Methylation signatures as biomarkers for non-invasive early detection of breast cancer: A systematic review of the literature

DNA Methylation as a Noninvasive Epigenetic Biomarker for the Detection of Cancer.

DNA methylation as a biomarker in breast cancer

Correlation Between CpG Methylation Profiles and Hormone Receptor Status in Breast Cancers.

Epigenome-wide DNA methylation and risk of breast cancer: a systematic review

Prognostic DNA Methylation Marker in Serum of Cancer Patients

DNA methylation markers for breast cancer prognosis

Identification of differentially methylated genes as diagnostic and prognostic biomarkers of breast cancer

DNA methylation as a triage marker for colposcopy referral in HPV-based cervical cancer screening: a systematic review and meta-analysis

A DNA Methylation-Based Panel for the Prognosis and Diagnosis of Patients With Breast Cancer and Its Mechanisms

DNA Methylation Signatures in Breast Cancer: A Systematic Review and Meta-Analysis

Utility of methylation markers in cervical cancer early detection: Appraisal of the state-of-the-science

Aberrant Promoter Methylation of Cancer-Related Genes in Human Breast Cancer

Promoter Methylation of BRCA1 in the Prognosis of Breast Cancer: a Meta-Analysis

Integrating DNA methylation measures to improve clinical risk assessment: are we there yet? The case of BRCA1 methylation marks to improve clinical risk assessment of breast cancer

Roadmap of DNA methylation in breast cancer identifies novel prognostic biomarkers

Assessment of DNA methylation status in early stages of breast cancer development

DNA methylation and breast cancer: A way forward (Review).

DNA Methylation Patterns Can Estimate Nonequivalent Outcomes of Breast Cancer with the Same Receptor Subtypes.

Determination of Genetic and Epigenetic Modifications-Related Prognostic Biomarkers of Breast Cancer: Genome High-Throughput Data Analysis